Academic Journal
Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts
| Title: | Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts |
|---|---|
| Authors: | Nguyen, Yann, Nocturne, Gaëtane, Henry, Julien, Ng, Wan-Fai, Belkhir, Rakiba, Desmoulins, Frédéric, Bergé, Elisabeth, Morel, Jacques, Perdriger, Aleth, Dernis, Emmanuelle, Devauchelle-Pensec, Valérie, Sène, Damien, Dieudé, Philippe, Couderc, Marion, Fauchais, Anne-Laure, Larroche, Claire, Vittecoq, Olivier, Salliot, Carine, Hachulla, Eric, Le Guern, Véronique, Gottenberg, Jacques-Eric, Mariette, Xavier, Seror, Raphaèle |
| Contributors: | Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Service de Rhumatologie CHU Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Physiologie & médecine expérimentale du Cœur et des Muscles U 1046 (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Fondation pour la Recherche Médicale.Société Française de Rhumatologie.Ministère du Travail, de la Santé et des Solidarités |
| Superior Title: | ISSN: 2665-9913 ; The Lancet Rheumatology ; https://hal.science/hal-04489543 ; The Lancet Rheumatology, 2024, ⟨10.1016/S2665-9913(23)00340-5⟩. |
| Publisher Information: | HAL CCSD Elsevier |
| Publication Year: | 2024 |
| Collection: | Université de Nantes: HAL-UNIV-NANTES |
| Subject Terms: | [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie |
| Description: | International audience ; Background: Sjögren's disease is a heterogenous autoimmune disease with a wide range of symptoms—including dryness, fatigue, and pain—in addition to systemic manifestations and an increased risk of lymphoma. We aimed to identify distinct subgroups of the disease, using cluster analysis based on subjective symptoms and clinical and biological manifestations, and to compare the prognoses of patients in these subgroups.Methods: This study included patients with Sjögren's disease from two independent cohorts in France: the cross-sectional Paris-Saclay cohort and the prospective Assessment of Systemic Signs and Evolution of Sjögren's Syndrome (ASSESS) cohort. We first used an unsupervised multiple correspondence analysis to identify clusters within the Paris-Saclay cohort using 26 variables comprising patient-reported symptoms and clinical and biological manifestations. Next, we validated these clusters using patients from the ASSESS cohort. Changes in disease activity (measured by the European Alliance of Associations for Rheumatology [EULAR] Sjögren's Syndrome Disease Activity Index [ESSDAI]), patient-acceptable symptom state (measured by the EULAR Sjögren's Syndrome Patient Reported Index [ESSPRI]), and lymphoma incidence during follow-up were compared between clusters. Finally, we compared our clusters with the symptom-based subgroups previously described by Tarn and colleagues.Findings: 534 patients from the Paris-Saclay cohort (502 [94%] women, 32 [6%] men, median age 54 years [IQR 43–64]), recruited between 1999 and 2022, and 395 patients from the ASSESS cohort (370 [94%] women, 25 [6%] men, median age 53 years [43–63]), recruited between 2006 and 2009, were included in this study. In both cohorts, hierarchical cluster analysis revealed three distinct subgroups of patients: those with B-cell active disease and low symptom burden (BALS), those with high systemic disease activity (HSA), and those with low systemic disease activity and high symptom burden (LSAHS). During follow-up in the ... |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | hal-04489543; https://hal.science/hal-04489543; https://hal.science/hal-04489543/document; https://hal.science/hal-04489543/file/2024%20Nguyen%20%20et%20al.,%20Identification.pdf |
| DOI: | 10.1016/S2665-9913(23)00340-5 |
| Availability: | https://doi.org/10.1016/S2665-9913(23)00340-5 https://hal.science/hal-04489543 https://hal.science/hal-04489543/document https://hal.science/hal-04489543/file/2024%20Nguyen%20%20et%20al.,%20Identification.pdf |
| Rights: | info:eu-repo/semantics/OpenAccess |
| Accession Number: | edsbas.F9320488 |
| Database: | BASE |
| Description not available. |